TARRYTOWN, N.Y.--(BUSINESS WIRE)--A new prognosis claim for the Siemens Healthineers Atellica IM High-Sensitivity Troponin I (TnIH) test 1 immediately advances care for at-risk cardiac patients in the ...
An analysis of a clinical trial of more than 2,500 people with Type 2 diabetes and kidney disease found that high levels of four biomarkers are strongly predictive for the development of heart and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback